Fellow's quick read · Infectious Diseases
Nontuberculous mycobacterial pulmonary disease
ATS / ERS / ESCMID / IDSA 2020 (Daley, Clin Infect Dis 2020;71(4):e1–e36) · reviewed 2026-07-10
Personal study digest for a new ID fellow. Recommendations are from the ATS/ERS/ESCMID/IDSA 2020 guideline (22 PICO questions, 31 GRADE recommendations — nearly all conditional, very-low certainty). Scope: pulmonary disease in adults WITHOUT cystic fibrosis or HIV. The "What's changed since 2020" section is reviewer synthesis of newer evidence, each claim cited. Not a substitute for the full guideline.
In one line
Diagnosis is a triad — symptoms + compatible CT + ≥2 positive sputum cultures of the same species — and meeting it does NOT mandate treatment. When you treat MAC, it is a macrolide-anchored 3-drug regimen for ≥12 months past culture conversion, and the macrolide is the drug you protect at all costs.◆When to suspect / diagnose
- All three required (Table 2): (1) pulmonary or systemic symptoms; (2) nodular or cavitary opacities on CXR, or CT showing bronchiectasis with multiple small nodules; (3) micro — ≥2 separate expectorated sputum cultures positive for the SAME species (subspecies for M. abscessus), OR ≥1 positive bronchial wash/lavage, OR a compatible transbronchial/lung biopsy plus culture.
- A single positive sputum is often environmental contamination; with ≥2 positive cultures the probability of clinically significant MAC disease rises to as high as ~98%.
- Pathogenicity varies: a single M. kansasii isolate in the right context can justify treatment, whereas low-virulence species (e.g. M. gordonae) need repeated positives + strong clinical/radiographic evidence.
- Meeting criteria ≠ treating. Weigh species pathogenicity, disease severity, comorbidities, and the patient's goals; "watchful waiting" is legitimate for indolent nodular-bronchiectatic disease.
◆Workup the fellow drives
- Speciate AND get susceptibilities that matter: for MAC and M. abscessus, baseline macrolide and amikacin MICs; for M. kansasii, rifampicin. Susceptibility-guided over empiric for these (weak recs) — but for most other drugs in-vitro/in-vivo correlation is unproven.
- M. abscessus is the exception that eats fellows alive: order a 14-day incubation macrolide MIC and/or erm(41) sequencing before you count the macrolide as active (see the subspecies card).
- Decide treat vs. watch up front, and document the shared decision — recurrence (including reinfection) is common in nodular-bronchiectatic disease.
- Screen the phenotype: older women with nodular-bronchiectatic ("Lady Windermere") vs. cavitary disease in COPD/prior TB — the split drives dosing frequency and whether to add a parenteral aminoglycoside.
◆Empiric & definitive therapy
Doses per Table 3: azithromycin 250–500 mg/d · rifampicin 10 mg/kg (450–600 mg)/d · ethambutol 15 mg/kg/d · amikacin IV 10–15 mg/kg/d (level-adjusted) · ALIS 590 mg inhaled once daily · isoniazid 5 mg/kg (≤300 mg)/d · moxifloxacin 400 mg/d · imipenem 0.5–1 g IV 2–3×/d · tigecycline 25–50 mg IV once daily · clofazimine 100–200 mg/d · linezolid 600 mg once daily.
| Scenario | Regimen (≥3 drugs) | Frequency & duration |
|---|---|---|
| MAC — nodular / bronchiectatic | Azithromycin + rifampicin + ethambutol | 3×/week; ≥12 mo after culture conversion |
| MAC — cavitary or advanced/severe | Azithromycin + rifampicin + ethambutol + amikacin IV (or streptomycin) ≥2–3 mo | Daily; ≥12 mo after conversion. Add parenteral aminoglycoside — the one MODERATE-certainty MAC rec. |
| MAC — refractory (still culture-positive after ≥6 mo) | Add ALIS (amikacin liposome inhalation) to the oral regimen (≥4 drugs) | Daily; STRONG rec — the only strong MAC treatment recommendation |
| M. kansasii (rifampicin-susceptible) | Rifampicin + ethambutol + (isoniazid or a macrolide) | Daily (noncavitary may be 3×/wk); ≥12 mo fixed, not 12 mo past conversion |
| M. xenopi | Rifampicin + ethambutol + (macrolide and/or moxifloxacin) ± amikacin if cavitary/severe | Daily; ≥12 mo after conversion. High mortality — treat aggressively, get expert help. |
| M. abscessus | Initial ≥3 active drugs: parenteral amikacin + imipenem (or cefoxitin) + tigecycline, plus oral (azithromycin, clofazimine, linezolid); continuation ≥2 oral/inhaled | Duration unsettled (shorter vs longer); expert consultation mandatory |
- Azithromycin over clarithromycin for MAC — better tolerated, fewer drug interactions, lower pill burden, once-daily, equal efficacy.
- Never a macrolide (or amikacin) as monotherapy or effective monotherapy — a ≥3-drug regimen exists chiefly to prevent acquired macrolide resistance; ethambutol is the critical resistance-preventing companion.
- Intermittent (3×/wk) is only for noncavitary nodular-bronchiectatic MAC — as effective as daily, better tolerated, no macrolide resistance emerged. Cavitary disease must be daily.
- Alternatives for intolerance/resistance: clofazimine, moxifloxacin, linezolid (some experts: bedaquiline, tedizolid).
◆Duration & stopping
- MAC and M. xenopi: ≥12 months after culture conversion (get monthly sputum cultures to define conversion — the clock starts at the first of consecutive negatives).
- M. kansasii: ≥12 months, fixed — not 12 months past conversion. If cultures have not converted by ~4 months on a rifampicin-based regimen, get expert consultation.
- M. abscessus: no consensus — the guideline explicitly punts to expert consultation on shorter vs. longer courses (most published series treated >12 months).
◆Key decisions a fellow owns
- Treat or watch — and if watching, follow serially rather than committing a frail patient to 18 months of toxic therapy.
- Protect the macrolide — confirm macrolide susceptibility (14-day/erm(41) for abscessus), and never let the regimen drift toward functional monotherapy.
- Add the aminoglycoside for cavitary/severe/macrolide-resistant MAC; do NOT use parenteral amikacin/streptomycin routinely for M. kansasii (strong rec against).
- Reserve ALIS for refractory disease (failed ≥6 months) — it is the guideline's only strong treatment rec and the FDA-approved indication.
- Consider adjuvant surgical resection in selected patients (localized/cavitary disease, drug-resistant isolates, hemoptysis, failure) — after expert consultation, by an experienced mycobacterial surgeon.
What's changed since 2020
Reviewer synthesis of newer evidence — not the guideline. Each claim cited; flags where the 2020 guideline is being overtaken.
- Inhaled amikacin is moving to the FRONT LINE — the biggest challenge to the 2020 text. The 2020 guideline recommended against ALIS in initial MAC therapy (it is approved only for refractory disease). Since then, front-line ALIS + azithromycin/ethambutol has met its endpoints in newly diagnosed MAC: ARISE (culture conversion 80.6% vs 63.9% by month 6, 78.8% vs 47.1% by month 7) and the phase 3b ENCORE trial (positive topline, met primary + all key secondary culture-conversion endpoints and respiratory-symptom score). Insmed plans a first-line supplemental NDA in H2 2026. ARISE, Ann Am Thorac Soc 2026;23(4):536–547, PMID 41915555 · ENCORE topline 23 Mar 2026, NCT04677569. Recency-sensitive — confirm the label/approval status.
- ALIS for refractory MAC stands (the one strong rec). Its basis, CONVERT (6-month culture conversion 29% vs 9%), was reaffirmed by a 2026 time-in-benefit (TWiST) post-hoc. CONVERT, Am J Respir Crit Care Med 2018;198:1559–1569 · TWiST post-hoc, Clin Ther 2026;48(7):610–614, PMID 42140798
- The oral pipeline has mostly disappointed. Epetraborole (oral leucyl-tRNA synthetase inhibitor) for refractory MAC — the phase 2/3 EBO-301 trial was stopped in Nov 2024 on interim phase-2 data (not for safety); only a post-hoc PRO signal (MACrO2 Δ 5.81, p=0.0433). SPR720 (oral gyrase-B inhibitor) showed no efficacy vs placebo with dose-dependent, reversible hepatic enzyme elevations in ~65%. EBO-301, AN2 Therapeutics release 13 Nov 2024 · SPR720, Sci Rep 2026;16(1), PMID 41720869. Recency-sensitive — investigational, paths uncertain.
- M. abscessus therapy is still un-standardized — but now being tested. The 2020 "shorter or longer + expert consult" reflects a true evidence vacuum; the international adaptive platform trial FORT is prospectively comparing regimens for M. abscessus pulmonary disease. FORT master protocol, BMJ Open 2025;15(9):e096188, PMID 40976660, NCT04310930
- No newer comprehensive society NTM treatment guideline has superseded the 2020 ATS/ERS/ESCMID/IDSA document — it remains the operative US/European reference. (PubMed / IDSA practice-guideline list, checked Jul 2026)
◆Anki cards minted this run
- NTM pulmonary disease diagnosis — ≥2 sputum cultures (same species) and diagnosis ≠ mandate to treat.
- MAC first-line regimen — azithromycin + rifampicin + ethambutol; 3×/week (nodular-bronchiectatic) vs daily (cavitary); ≥12 mo after conversion.
- ALIS/Arikayce — strong rec only for REFRACTORY MAC (CONVERT 29% vs 9%); front-line ARISE/ENCORE pending.
- M. abscessus subspecies — massiliense (nonfunctional erm(41), macrolide active) vs abscessus/bolletii (functional erm(41), inducible resistance).
Sources: ATS/ERS/ESCMID/IDSA NTM-PD guideline — Daley et al, Clin Infect Dis 2020;71(4):e1–e36 (doi:10.1093/cid/ciaa241). Currency: ARISE (Ann Am Thorac Soc 2026;23(4):536–547, PMID 41915555, doi:10.1093/annalsats/aaoaf064); ENCORE phase 3b topline (Insmed, 23 Mar 2026, NCT04677569); CONVERT (Am J Respir Crit Care Med 2018;198:1559–1569) and TWiST post-hoc (Clin Ther 2026;48(7):610–614, PMID 42140798, doi:10.1016/j.clinthera.2026.04.007); epetraborole EBO-301 (AN2 Therapeutics, 13 Nov 2024); SPR720 (Sci Rep 2026;16(1), PMID 41720869, doi:10.1038/s41598-026-40505-7); FORT platform trial (BMJ Open 2025;15(9):e096188, PMID 40976660, doi:10.1136/bmjopen-2024-096188). Literature via PubMed + ClinicalTrials.gov + web, Jul 2026.